Table 1.
Minority representation in major cardiovascular outcome trials in type 2 diabetes.
| N | Drug (vs placebo) | Percentage total | Number and percentage | |
| black or African American | US or North American participants | |||
| EXAMINE (NCT00968708; Takeda) [29] | 5380 | Alogliptin | 4.0% | 744/5380 (13.9%) |
| EMPA‐REG OUTCOME (NCT01131676) [30] | 7064 | Empagliflozin | 5.1% | 1394/7064 (19.7%) (participants also include Australia and New Zealand) |
| SAVOR‐TIMI 53 (NCT01107886) [31] | 16,492 | Saxagliptin | 3.4% | 5266/16492 (31.9%) |
| ELIXA (NCT01147250) [32] | 6068 | Lixisenatide | 3.6% | 696/6068 (11.5%) |
| TECOS (NCT00790205) [33] | 14,671 | Sitagliptin | 3.0% | 2045/14671 (13.9%) |
| LEADER (NCT01179048) [34] | 9340 | Liraglutide | 8.3% | 2847/9340 (30%) |
| SUSTAIN‐6 (NCT01720446) [35] | 3297 | Semaglutide | 6.7% | 1137/3297 (34.5%) |
Table adapted from supplement: Hoppe C, Kerr D. Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes. Lancet Diabetes Endocrinol 2017; 5: 13. [28].